Novartis bids to buy U.S. vaccine maker Chiron

Share this article:
Novartis today offered $4.5 billion to purchase the remaining shares of U.S. drugmaker Chiron in a bid to gain a firm foothold in the vaccines business.
Novartis, currently owns 42.2 percent of Chiron, which is based in Emeryville, Calif. Chiron just broke even in the second quarter of 2005 as the company struggled to produce enough of its flu vaccine to supply to customers before the coming winter, due to problems at manufacturing plants in Germany and the U.K.
However, after a favorable FDA inspection report of a Chiron plant in Liverpool, England, the company is expected to start supplying its flu vaccine again for the 2005-2006 season.
Analysts said the deal would give Novartis access to a range of vaccines at a time when interest in vaccination is growing amid fears of a bird flu pandemic.
Novartis has already spent $8 billion this year on two generics companies and spent $660 million in cash to purchase Bristol-Myers Squibb's portfolio of non-prescription drugs.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.